Armata Pharmaceuticals, Inc. (ARMP) Stock

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

Armata Pharmaceuticals, Inc. is led by CEO Deborah L. Birx, employs 60 people, headquartered in US, publicly traded since 1994.

Armata Pharmaceuticals, Inc. (ARMP) stock trades at $3.64 with a market capitalization of $135.34M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.52, reflecting a net loss over the last twelve months, a negative price-to-book of -0.44, reflecting negative shareholders' equity, price-to-sales of 30.94. Over the past 52 weeks the stock has ranged between $2.75 and $16.34, and currently trades 77.7% below its 52-week high.

On profitability, Armata Pharmaceuticals, Inc. generates a return on equity (ROE) of 89.70% (not meaningful, as shareholders' equity is negative), return on capital employed of 25.40%, an operating margin of -620.00%, a net profit margin of -95.54%.

Official website: www.armatapharma.com

Armata Pharmaceuticals, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Armata Pharmaceuticals, Inc. reported revenue of $0 rising to $5.0M. Compounded, revenue has grown 38.0% a year over five years, -5.9% over three, 0.0% over the last twelve months. Net profit fell to $-174.0M.

Operating margin went from -8991.5% in 2016 to -636.7% in 2025, a gain of 8354.9 percentage points. The most recent net margin is -95.54%. On a trailing twelve-month basis to Jun '26, revenue is $4.0M and net profit $-192.0M.

Borrowings rose from $1.0M to $288.0M, cash from operations was $-26.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 28.0% over five years, and was 79.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Armata Pharmaceuticals, Inc. (ARMP) — frequently asked questions